“His favourite subject ? Nanofitins^®. These small proteins, coming from bacteria discovered in Yellowstone Park geysers, exhibit the same functionnalities as the antibodies produced by our body.”

On February 26, 2013, Nadège Prel, Business Development manager at Affilogic presented their Nanofitins^®, proteins alternative to therapeutic antibodies at the “Partnering with France” Workshop during Bio Partnering North in Vancouver.

San Diego, June 12-14, 2013

The annual Convention CALBIO (the largest « Life Sciences » of the West Coast of the United-States), jointly organized by BayBio and BioCom, gathers every year more than 1000 participants from the Parmaceutical and Biotechnology industries.

Read more on CALBIO 2013

Affilogic’s founder and CEO, Olivier Kitten, presented the Nanofitins^® at the French Embassy in Japan, for a partnering event organized by UBIFRANCE with Japanese pharmaceutical companies, following BIO Asia congress on January 31^st, 2013.

“(…) In 2011, Affilogic obtained a Research grant from the European Commission to develop therapeutic agents for Crohn’s disease and Ulcerative colitis. The goal of this project is to generate Nanofitins^® inhibiting TNF that could be administered orally. (…) On top of oral administration, we are investigating the possibility to formulate Nanofitins^®within ointments and eye drops.(…)”

 

Download the article from Bio Nikkei about AFFILOGIC

For 3 years, the biotech company from Nantes Affilogic is engineering Nanofitins used as an alternative to antibodies for diagnostic applications or to treat pathologies such as Crohn Disease, Psoriasis, AMD (Age-related Macular Degenration), Rheumatoid Arthritis…

 

(…) Seven “pilot” projects are in the hands of Pharma companies awaiting validation.

These proteins, 20 time smaller than antibodies, can be very easily conjugated with other molecules and have applications in diagnostics and for the treatment of pathologies. Cost-effective production costs could enable, eventually, to propose targeted and individualized treatments for same price as antibiotics. (…)”